Back to top
more

Neogen (NEOG)

(Real Time Quote from BATS)

$4.78 USD

4.78
1,889,514

+0.10 (2.14%)

Updated Aug 5, 2025 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Neogen (NEOG) give a sense of how its business performed in the quarter ended August 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Neogen (NEOG) Misses Q1 Earnings Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -30% and 0.39%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insights Into Neogen (NEOG) Q1: Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Neogen (NEOG) for the quarter ended August 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -22.22% and 22.44%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Neogen (NEOG) Stock?

by Zacks Equity Research

Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.

Zacks Equity Research

InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

InnovAge (INNV) delivered earnings and revenue surprises of 50% and 4.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neogen (NEOG) Down 1.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

by Zacks Equity Research

NEOG faces intense competition, which could affect the marketability and profitability of its products.

Zacks Equity Research

Is the Options Market Predicting a Spike in Neogen (NEOG) Stock?

by Zacks Equity Research

Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.

Zacks Equity Research

Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash

by Zacks Equity Research

Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.

Zacks Equity Research

Neogen (NEOG) Lags Q4 Earnings Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -16.67% and 5.14%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial

by Zacks Equity Research

Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.

Zacks Equity Research

Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch

by Zacks Equity Research

Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.

Zacks Equity Research

Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.

Zacks Equity Research

Neogen's (NEOG) MDS Secures New Contract From USDA FSIS

by Zacks Equity Research

Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.

Zacks Equity Research

Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Do Options Traders Know Something About Neogen (NEOG) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Neogen (NEOG) stock based on the movements in the options market lately.

Zacks Equity Research

Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition

by Zacks Equity Research

Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.

Zacks Equity Research

Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing

by Zacks Equity Research

Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.

Zacks Equity Research

Company News for Apr 10, 2024

by Zacks Equity Research

Companies in The News Are: MRNA, MRK, COIN, BN, NEOG

Zacks Equity Research

Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands

by Zacks Equity Research

Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.

Zacks Equity Research

Here's What Key Metrics Tell Us About Neogen (NEOG) Q3 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended February 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -14.29% and 0.49%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neogen (NEOG) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Neogen (NEOG), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended February 2024.